Oxford Immunotec Global 10-Q 6 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Jul. 25, 2019
Document Information [Line Items]
Entity Registrant Name	Oxford Immunotec Global PLC
Entity Central Index Key	0001586049
Trading Symbol	oxfd
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		26,830,721
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Ordinary Shares

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 187,291	$ 192,844
Accounts receivable, net	13,778	9,158
Other receivable	9,115	4,500
Inventory, net	9,957	7,767
Prepaid expenses and other assets	3,199	2,511
Total current assets	223,340	216,780
Restricted cash, non-current	100	100
Other receivable, non-current		4,500
Property and equipment, net	6,658	7,144
Operating lease right-of-use assets	6,892
Goodwill	2,483	2,483
Net Carrying Amount, Finite-Lived Intangible Assets	50	61
Deferred tax asset	2,508	1,052
Total assets	242,031	232,120
Liabilities and shareholders' equity
Accounts payable	2,519	2,801
Accrued liabilities	9,227	10,891
Current portion of operating lease liability	480
Settlement liability	4,289	4,106
Deferred income	214	125
Current portion of loans payable		85
Total current liabilities	16,729	18,008
Long-term portion of operating lease liability	7,489
Long-term portion of loans payable	30	106
Total liabilities	24,248	18,114
Commitments and contingencies (Note 12)
Shareholders' equity:
Ordinary shares, £0.006705 nominal value; 38,978,604 shares authorized at June 30, 2019 and December 31, 2018, and 26,807,101 and 26,439,334 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	280	276
Additional paid-in capital	307,882	303,015
Accumulated deficit	(81,668)	(80,762)
Accumulated other comprehensive loss	(8,711)	(8,523)
Total shareholders' equity	217,783	214,006
Total liabilities and shareholders' equity	$ 242,031	$ 232,120

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - £ / shares	Jun. 30, 2019	Dec. 31, 2018
Common stock, nominal value (in GBP per share)	£ 0.006705	£ 0.006705
Common stock, shares authorized (in shares)	38,978,604	38,978,604
Common stock, shares issued (in shares)	26,807,101	26,439,334
Common stock, shares outstanding (in shares)	26,807,101	26,439,334

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Revenue	$ 19,588	$ 16,657	$ 34,377	$ 28,336
Cost of revenue:
Cost of goods and services sold	5,400	4,538	9,628	8,297
Gross profit	14,188	12,119	24,749	20,039
Operating expenses:
Research and development	2,089	1,849	4,413	4,215
Sales and marketing	7,485	7,072	13,764	14,223
General and administrative	5,491	5,657	10,699	11,217
Settlement expense	104	1,560	203	1,767
Total operating expenses	15,169	16,138	29,079	31,422
Operating loss from continuing operations	(981)	(4,019)	(4,330)	(11,383)
Other expense:
Interest income (expense), net	1,162	(734)	2,362	(1,338)
Foreign exchange gains (losses)	291	(151)	(593)	(254)
Other income (expense)	42	(195)	42	(247)
Income (loss) from continuing operations before income taxes	514	(5,099)	(2,519)	(13,222)
Income tax benefit (expense) from continuing operations	76	(634)	1,613	(697)
Income (loss) from continuing operations	590	(5,733)	(906)	(13,919)
Discontinued operations:
Loss from discontinued operations before income taxes		(738)		(2,878)
Income tax expense
Loss from discontinued operations		(738)		(2,878)
Net income (loss)	$ 590	$ (6,471)	$ (906)	$ (16,797)
Net income (loss) per ordinary share - basic
Income (loss) from continuing operations (in dollars per share)	$ 0.02	$ (0.22)	$ (0.03)	$ (0.54)
Loss from discontinued operations (in dollars per share)		(0.03)		(0.11)
Net income (loss) (in dollars per share)	0.02	(0.25)	(0.03)	(0.65)
Net income (loss) per ordinary share - diluted:
Income (loss) from continuing operations (in dollars per share)	0.02	(0.22)	(0.03)	(0.54)
Loss from discontinued operations (in dollars per share)		(0.03)		(0.11)
Net income (loss) (in dollars per share)	$ 0.02	$ (0.25)	$ (0.03)	$ (0.65)
Weighted-average shares used to compute net income (loss) per ordinary share - basic (in shares)	26,625,572	25,845,124	26,571,025	25,782,366
Weighted-average shares used to compute net income (loss) per ordinary share - diluted (in shares)	26,889,232	25,845,124	26,571,025	25,782,366
Product [Member]
Revenue:
Revenue	$ 18,666	$ 15,012	$ 32,507	$ 25,141
Cost of revenue:
Cost of goods and services sold	5,078	3,477	8,993	6,129
Service [Member]
Revenue:
Revenue	922	1,645	1,870	3,195
Cost of revenue:
Cost of goods and services sold	$ 322	$ 1,061	$ 635	$ 2,168

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net loss	$ 590	$ (6,471)	$ (906)	$ (16,797)
Other comprehensive loss:
Foreign currency translation adjustment, including tax charges / (benefits) of $379, $(539), $60, and $(918), respectively	(1,355)	(1,521)	(188)	(964)
Other comprehensive loss, net of tax	(1,355)	(1,521)	(188)	(964)
Total comprehensive loss	$ (765)	$ (7,992)	$ (1,094)	$ (17,761)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Other Comprehensive Loss (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Foreign currency translation adjustment, tax charges / (benefits)	$ 379	$ (539)	$ 60	$ (918)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2017	$ 269	$ 294,613	$ (201,541)	$ (5,712)	$ 87,629
Exercise of share options	2	82			84
Share-based compensation expense		1,824			1,824
Tax on vesting of restricted share units		(156)			(156)
Other comprehensive income				557	557
Net income (loss)			(10,326)		(10,326)
Balance at Mar. 31, 2018	271	296,363	(211,867)	(5,155)	79,612
Balance at Dec. 31, 2017	269	294,613	(201,541)	(5,712)	87,629
Other comprehensive income					(964)
Net income (loss)					(16,797)
Balance at Jun. 30, 2018	272	297,906	(218,338)	(6,676)	73,164
Balance at Mar. 31, 2018	271	296,363	(211,867)	(5,155)	79,612
Exercise of share options	1	620			621
Share-based compensation expense		923			923
Other comprehensive income				(1,521)	(1,521)
Net income (loss)			(6,471)		(6,471)
Balance at Jun. 30, 2018	272	297,906	(218,338)	(6,676)	73,164
Balance at Dec. 31, 2018	276	303,015	(80,762)	(8,523)	214,006
Exercise of share options	2	1,800			1,802
Share-based compensation expense		845			845
Tax on vesting of restricted share units		(145)			(145)
Other comprehensive income				1,167	1,167
Net income (loss)			(1,496)		(1,496)
Balance at Mar. 31, 2019	278	305,515	(82,258)	(7,356)	216,179
Balance at Dec. 31, 2018	276	303,015	(80,762)	(8,523)	214,006
Other comprehensive income					(188)
Net income (loss)					(906)
Balance at Jun. 30, 2019	280	307,882	(81,668)	(8,711)	217,783
Balance at Mar. 31, 2019	278	305,515	(82,258)	(7,356)	216,179
Exercise of share options	2	1,531			1,533
Share-based compensation expense		846			846
Tax on vesting of restricted share units		(10)			(10)
Other comprehensive income				(1,355)	(1,355)
Net income (loss)			590		590
Balance at Jun. 30, 2019	$ 280	$ 307,882	$ (81,668)	$ (8,711)	$ 217,783

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net loss	$ (906)	$ (16,797)
Less: Net loss from discontinued operations, net of tax		(2,878)
Net loss from continuing operations	(906)	(13,919)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Depreciation and amortization expense	900	657
Non-cash rent expense	112
Accretion and amortization of loan fees and non-cash interest income	(100)	280
Share-based compensation expense	1,691	2,603
Loss on disposal of property and equipment	20	83
Deferred income taxes	(1,518)	728
Changes in operating assets and liabilities:
Accounts receivable, net	(4,695)	(986)
Inventory , net	(2,244)	253
Prepaid expenses and other assets	(858)	(858)
Accounts payable	(194)	(8,131)
Accrued liabilities	(524)	(589)
Deferred income	88	12
Other liabilities, net		(179)
Net cash used in operating activities from continuing operations	(8,228)	(20,046)
Cash flows from investing activities
Purchases of property and equipment	(520)	(3,389)
Net cash used in investing activities from continuing operations	(520)	(3,389)
Cash flows from financing activities
Proceeds from exercise of share options	3,332	814
Payments of tax withheld on exercises of options and vesting of restricted share units	(155)	(265)
Payments on capital lease		(38)
Net cash provided by financing activities from continuing operations	3,177	511
Net cash flows of continuing operations	(5,571)	(22,924)
Cash flows from discontinued operations
Net operating cash flows provided by discontinued operations		1,057
Net investing cash flows used in discontinued operations		(1,759)
Net financing cash flows used in discontinued operations		(7)
Net cash flows of discontinued operations		(709)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	18	(436)
Net decrease in cash, cash equivalents, and restricted cash	(5,553)	(24,069)
Cash, cash equivalents, and restricted cash at beginning of period	192,944	90,532
Cash, cash equivalents, and restricted cash at end of period	$ 187,391	$ 66,463

Note 1 - Business and Basis of

Note 1 - Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Notes to Unaudited Condensed Consolidated Financial Statements June 30, 2019 1. Description of business Oxford Immunotec Global PLC, or the Company, is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for immunology and infectious disease by leveraging the technological, product development, manufacturing, quality, regulatory, and sales and marketing capabilities it has developed over its seventeen TB Discontinued operations The Company reports the results of operations of a business that either has been disposed of or is classified as held for sale, in accordance with Accounting Standards Codification, or ASC, 360, Property, Plant, and Equipment 205, Presentation of Financial Statements As discussed in Note 13, Discontinued operations September 25, 2018, November 6, 2018 $170 210 three Unaudited interim financial statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions to Form 10 10 X. not June 30, 2019 three six June 30, 2019 2018 six June 30, 2019 2018 not The consolidated balance sheet presented as of December 31, 2018 2018 10 December 31, 2018, March 28, 2019, 2018 10 Cash, cash equivalents, and restricted cash The Company considers all highly liquid investments purchased with maturities at acquisition of three not Restricted cash relates to collateral for procurement cards issued by a U.S. commercial bank. Cash, cash equivalents, and restricted cash consists of the following: (in thousands) June 30, 2019 December 31, 2018 Cash and cash equivalents $ 187,291 $ 192,844 Restricted cash, non-current 100 100 Total cash, cash equivalents, and restricted cash $ 187,391 $ 192,944 Revenues The Company’s revenues include product and service revenues. In general, revenue from diagnostic test kit sales and related accessories is recognized at a point in time based upon contractual rates. However, for contracts with tiered pricing provisions, if the tiered pricing constitutes a material right and spans across multiple reporting periods, the Company estimates the total transaction price at the beginning of each reset period ( i.e. 2. Revenue As of June 30, 2019 $13.8 three six June 30, 2019 no no June 30, 2019 one Revenue expected to be recognized in any future year related to remaining performance obligations is not Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations. Other than the following discussion regarding leases, the remainder of the significant accounting estimates and policies used in preparation of the condensed consolidated financial statements disclosed in Note 1. Description of business and significant accounting policies 2018 10 Leases In February 2016, 2016 02, Leases 2016 02, 2016 02 January 1, 2019, At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one not one not January 1, 2019 2016 02. In accordance with the guidance in ASU 2016 02, three e.g. e.g. e.g. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may not Recently a dopted a ccounting p ronouncements In February 2016, 2016 02, 12 2016 02 2016 02 January 1, 2019 2016 02, 12 not 2016 02, $7.2 $8.2 January 1, 2019. 2016 02 not 12. Commitments In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07. 2018 07 2018 07 January 1, 2019. 2018 07 not Recently i ssued but not a ccounting p ronouncements In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. not 2016 13 In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. not 2017 04 In August 2018, No. 2018 13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, 2018 13, 3 2018 13 December 15, 2019 not 2018 13.

Note 2 - Revenue

Note 2 - Revenue	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	2. On November 6, 2018, 13, Discontinued operations. The following tables present the Company’s revenues disaggregated by type: Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Revenue Product $ 18,666 $ 15,012 $ 32,507 $ 25,141 Service 922 1,645 1,870 3,195 Total revenue $ 19,588 $ 16,657 $ 34,377 $ 28,336 Service revenue for the three six June 30, 2018 $855,000 $1.6 2018. The following tables reflect revenue by geography (United States, Europe and rest of world, or Europe and ROW, and Asia): Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Revenue United States $ 7,768 $ 5,041 $ 13,299 $ 8,739 Europe and ROW 2,199 2,237 4,961 4,473 Asia 9,621 9,379 16,117 15,124 Total revenue $ 19,588 $ 16,657 $ 34,377 $ 28,336 United States revenue for the three six June 30, 2018 $855,000 $1.6 2018.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three Level 1—Observable Level 2—Observable 1 not Level 3—Unobservable no This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short term nature. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The tables below present information about the Company’s financial assets measured at fair value on a recurring basis as of the respective dates and indicate the level of the fair value hierarchy utilized to determine such fair values. The Company had no June 30, 2019 (in thousands) Total Level 1 Level 2 Level 3 Assets: U.S. Government money market funds $ 10,833 $ 10,833 $ — $ — Tri-party repurchase agreements (collateralized by at least 102% U.S. Treasury and Agency Securities) 165,642 165,642 — — Total $ 176,475 $ 176,475 $ — $ — December 31, 2018 (in thousands) Total Level 1 Level 2 Level 3 Assets: U.S. Government money market funds $ 19,812 $ 19,812 $ — $ — Tri-party repurchase agreements (collateralized by at least 102% U.S. Treasury and Agency Securities) 165,157 165,157 — — Total $ 184,969 $ 184,969 $ — $ — Money market funds and repurchase agreements were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 1 The Company had a term loan outstanding under an agreement with MidCap Financial Trust, or MidCap, at June 30, 2018 , 2 $32.3 $2.3 8. Loans payable

Note 4 - Accounts Receivable, N

Note 4 - Accounts Receivable, Net	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	4. Accounts receivable, net, consisted of the following as of: (in thousands) June 30, 2019 December 31, 2018 Accounts receivable $ 13,888 $ 9,246 Less allowance for uncollectible accounts receivable (110 ) (88 ) Accounts receivable, net $ 13,778 $ 9,158

Note 5 - Inventory, Net

Note 5 - Inventory, Net	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory, net consisted of the following as of: (in thousands) June 30, 2019 December 31, 2018 Raw materials $ 7,847 $ 6,169 Work in progress 47 190 Finished goods 2,063 1,408 Inventory, net $ 9,957 $ 7,767

Note 6 - Goodwill and Acquired

Note 6 - Goodwill and Acquired Intangible Assets	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. The Company has one 13. Discontinued operations 350, Intangibles – Goodwill and Other third 2018 $1.5 $2.5 June 30, 2019 December 31, 2018 Acquired intangible assets consisted of the following as of June 30, 2019 December 31, 2018 As of June 30, 2019 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Licenses 5-10 $ 652 $ 602 $ 50 Total $ 652 $ 602 $ 50 As of December 31, 2018 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Licenses 5-10 $ 652 $ 591 $ 61 Total $ 652 $ 591 $ 61

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued liabilities consisted of the following as of: (in thousands) June 30, 2019 December 31, 2018 Employee related expenses $ 4,339 $ 5,536 Corporate tax 1,616 1,616 Professional services 893 863 Royalties 836 1,354 Other accrued liabilities 1,543 1,522 Total accrued liabilities $ 9,227 $ 10,891

Note 8 - Loans Payable

Note 8 - Loans Payable	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	8. On October 4, 2016, $40 $30 five 7.60% first 24 48 $10 five 4.45%. 0.50% $10 $60 Approximately $32.3 $2.3 $2.1 June 30, 2018 $30

Note 9 - Share Capital

Note 9 - Share Capital	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. During the six June 30, 2019 323,181 44,586 twelve December 31, 2018 694,322 83,378

Note 10 - Share Option and Equi

Note 10 - Share Option and Equity Incentive Plan	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. The impact on the Company’s results of operations from share-based compensation was as follows: Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Cost of revenue $ 31 $ 59 $ 35 $ 125 Research and development 130 162 112 380 Sales and marketing 354 70 578 637 General and administrative 331 552 966 1,461 Total continuing operations 846 843 1,691 2,603 Discontinued operations - 79 - 143 Total share-based compensation $ 846 $ 922 $ 1,691 $ 2,746 In November 2013, 2013 2013 2013 2017 During the three June 30, 2019 425,328 $14.44 $16.42 2013 2013 three June 30, 2019 $7.36 six June 30, 2019 430,328 $14.44 $16.42 2013 2013 six June 30, 2019 $7.35 ten During the three six June 30, 2019 142,544 40% second 30% third 30% fourth For the three June 30, 2019 $627,000 $219,000, three June 30, 2018 $713,000 $209,000, For the six June 30, 2019 $1.3 $415,000, six June 30, 2018 $1.7 $1.0 As of June 30, 2019 $5.6 $3.7 2.7 3

Note 11 - Net Loss Per Share

Note 11 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	11. Three months ended June 30, Six months ended June 30, ($ amounts in thousands) 2019 2018 2019 2018 Numerator Income (loss) from continuing operations $ 590 $ (5,733 ) $ (906 ) $ (13,919 ) Loss from discontinued operations - (738 ) - (2,878 ) Net income (loss) $ 590 $ (6,471 ) $ (906 ) $ (16,797 ) Denominator Weighted-average ordinary shares - basic 26,625,572 25,845,124 26,571,025 25,782,366 Dilutive effect of ordinary share equivalents resulting from ordinary share options and RSUs 263,660 - - - Weighted-average ordinary shares - diluted 26,889,232 25,845,124 26,571,025 25,782,366 The following numbers of outstanding ordinary share options and unvested RSUs were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Options to purchase ordinary shares - 536,998 256,533 499,550 Unvested RSUs - 343,774 59,904 343,774

Note 12 - Commitments

Note 12 - Commitments	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	12. Operating leases The Company has operating leases for real estate and non-real estate in the United States, United Kingdom, China, Japan, and South Korea. One such operating lease is a sublease for real estate. The Company does not The Company leases office, storage/warehouse, laboratory and manufacturing space in Abingdon, U.K., which leases are due to expire at various dates from December 31, 2020 June 18, 2033. March 1, 2013, five August 2015, two October 31, 2020. 7,600 22,100 $36,000 $12,000 2016, $39,000 one five In June 2018, June 2033 $39,000 $79,000 In connection with the sale of our U.S. Laboratory Services Business to Quest, the Company entered into a sublease with Quest for approximately 9,000 November 2020. $17,000 Many of the Company’s leases contain options to renew and extend lease terms and options to terminate leases early. Reflected in the right-of-use asset and lease liability on the Company’s balance sheet are the periods provided by renewal and extension options that the Company is reasonably certain to exercise, as well as the periods provided by termination options that the Company is reasonably certain to not The Company has existing leases that include variable lease and non-lease components that are not In calculating the present value of future lease payments, the Company has elected to utilize its incremental borrowing rate based on the remaining lease term at the date of adoption. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and has allocated all of the contract consideration across lease components only. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability for leases being greater than if the policy election was not e.g. not June 30, 2019 $6.9 $8.0 The elements of lease expense were as follows: ($ amounts in thousands) Three months ended June 30, 2019 Six months ended June 30, 2019 Lease Cost Operating lease cost $ 319 $ 641 Short-term lease cost 39 229 Variable lease cost 116 271 Total lease cost $ 474 $ 1,141 Other Information Cash paid for amounts included in the measurement of lease liabilities $ 252 $ 515 Operating lease liabilities arising from obtaining right-of-use assets - - Operating Leases Weighted average remaining lease term (in years) 12.7 12.7 Operating Leases Weighted average discount rate 7.8 % 7.8 % Future lease payments required under non-cancelable operating leases in effect as of June 30, 2019 (in thousands) June 30, 2019 2019 $ 494 2020 1,029 2021 978 2022 972 2023 972 Thereafter 8,453 Total lease payments 12,898 Less: imputed interest (4,929 ) Total operating lease liabilities $ 7,969 The Company adopted ASC 842, Leases January 1, 2019, December 31, 2018 (in thousands) December 31, 2018 2019 $ 2,024 2020 1,848 2021 972 2022 855 2023 855 Thereafter 7,558 Total minimum lease payments $ 14,112 Purchase commitments Future minimum payments required under purchase obligations in effect as of June 30, 2019 (in thousands) Purchase obligations 2019 (six months) $ 7,795 2020 1,200 2021 1,200 2022 370 2023 370 Thereafter - Total minimum payments $ 10,935

Note 13 - Discontinued Operatio

Note 13 - Discontinued Operations	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	13. As previously disclosed, on September 25, 2018, $170 $32.3 $2.3 8. Loans payable As contemplated in the Purchase Agreement, Oxford Immunotec USA, Inc., a Delaware corporation and a newly formed wholly owned subsidiary of Oxford Limited, or Oxford USA, joined the Purchase Agreement by way of a Joinder Agreement dated October 1, 2018. The Transaction was consummated in accordance with the terms and conditions of the Purchase Agreement on November 6, 2018, At the time of sale, the U.S. Laboratory Services Business had a carrying value of $27.9 $146.0 three December 31, 2018 Additionally, pursuant to the terms of the Purchase Agreement, the parties entered into certain ancillary agreements as of the Closing Date, including: (i) a transitional services agreement, or TSA, that will continue, unless otherwise terminated, until each service included in the TSA has been completed, (ii) a technology license agreement that will remain in effect until the date of expiration or lapse of the last "Blood Stability Patent" to expire or lapse, and (iii) a long-term supply agreement, or the Supply Agreement, pursuant to which Oxford USA agreed to sell, and Quest agreed to purchase, T-SPOT. TB seven TB In conjunction with the Purchase Agreement, Quest agreed to purchase kits and accessories from the Company for an initial period of seven June 12, 2019, During the three six June 30, 2018 $3.3 $5.5 The following table presents the results of discontinued operations, which solely relate to 2018 (in thousands) Three months ended June 30, 2018 Six months ended June 30, 2018 Major classes of line items constituting loss from discontinued operations before income taxes: Service revenue $ 15,944 $ 27,819 Cost of service revenue 11,451 20,470 Gross profit 4,493 7,349 Research and development 1,534 2,912 Sales and marketing 2,235 4,489 General and administrative 1,462 2,826 Loss from discontinued operations before income taxes (738 ) (2,878 ) Income tax expense — — Loss from discontinued operations $ (738 ) $ (2,878 )

Note 14 - Subsequent Events

Note 14 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	14. On July 11, 2019, March October 8, 2013, April 22, 2015, November 3, 2016, December 20, 2017, June 5, 2018 September 17, 2018, TB 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Discontinued Operations, Policy [Policy Text Block]	Discontinued operations The Company reports the results of operations of a business that either has been disposed of or is classified as held for sale, in accordance with Accounting Standards Codification, or ASC, 360, Property, Plant, and Equipment 205, Presentation of Financial Statements As discussed in Note 13, Discontinued operations September 25, 2018, November 6, 2018 $170 210 three
Basis of Accounting, Policy [Policy Text Block]	Unaudited interim financial statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions to Form 10 10 X. not June 30, 2019 three six June 30, 2019 2018 six June 30, 2019 2018 not The consolidated balance sheet presented as of December 31, 2018 2018 10 December 31, 2018, March 28, 2019, 2018 10
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, cash equivalents, and restricted cash The Company considers all highly liquid investments purchased with maturities at acquisition of three not Restricted cash relates to collateral for procurement cards issued by a U.S. commercial bank. Cash, cash equivalents, and restricted cash consists of the following: (in thousands) June 30, 2019 December 31, 2018 Cash and cash equivalents $ 187,291 $ 192,844 Restricted cash, non-current 100 100 Total cash, cash equivalents, and restricted cash $ 187,391 $ 192,944
Revenue from Contract with Customer [Policy Text Block]	Revenues The Company’s revenues include product and service revenues. In general, revenue from diagnostic test kit sales and related accessories is recognized at a point in time based upon contractual rates. However, for contracts with tiered pricing provisions, if the tiered pricing constitutes a material right and spans across multiple reporting periods, the Company estimates the total transaction price at the beginning of each reset period ( i.e. 2. Revenue As of June 30, 2019 $13.8 three six June 30, 2019 no no June 30, 2019 one Revenue expected to be recognized in any future year related to remaining performance obligations is not Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations. Other than the following discussion regarding leases, the remainder of the significant accounting estimates and policies used in preparation of the condensed consolidated financial statements disclosed in Note 1. Description of business and significant accounting policies 2018 10
Lessee, Leases [Policy Text Block]	Leases In February 2016, 2016 02, Leases 2016 02, 2016 02 January 1, 2019, At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Most leases with a term greater than one not one not January 1, 2019 2016 02. In accordance with the guidance in ASU 2016 02, three e.g. e.g. e.g. Although separation of lease and non-lease components is required, certain practical expedients are available. Entities may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently a dopted a ccounting p ronouncements In February 2016, 2016 02, 12 2016 02 2016 02 January 1, 2019 2016 02, 12 not 2016 02, $7.2 $8.2 January 1, 2019. 2016 02 not 12. Commitments In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07. 2018 07 2018 07 January 1, 2019. 2018 07 not Recently i ssued but not a ccounting p ronouncements In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. not 2016 13 In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. not 2017 04 In August 2018, No. 2018 13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, 2018 13, 3 2018 13 December 15, 2019 not 2018 13.

Note 1 - Business and Basis o_2

Note 1 - Business and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	(in thousands) June 30, 2019 December 31, 2018 Cash and cash equivalents $ 187,291 $ 192,844 Restricted cash, non-current 100 100 Total cash, cash equivalents, and restricted cash $ 187,391 $ 192,944

Note 2 - Revenue (Tables)

Note 2 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Revenue Product $ 18,666 $ 15,012 $ 32,507 $ 25,141 Service 922 1,645 1,870 3,195 Total revenue $ 19,588 $ 16,657 $ 34,377 $ 28,336 Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Revenue United States $ 7,768 $ 5,041 $ 13,299 $ 8,739 Europe and ROW 2,199 2,237 4,961 4,473 Asia 9,621 9,379 16,117 15,124 Total revenue $ 19,588 $ 16,657 $ 34,377 $ 28,336

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, 2019 (in thousands) Total Level 1 Level 2 Level 3 Assets: U.S. Government money market funds $ 10,833 $ 10,833 $ — $ — Tri-party repurchase agreements (collateralized by at least 102% U.S. Treasury and Agency Securities) 165,642 165,642 — — Total $ 176,475 $ 176,475 $ — $ — December 31, 2018 (in thousands) Total Level 1 Level 2 Level 3 Assets: U.S. Government money market funds $ 19,812 $ 19,812 $ — $ — Tri-party repurchase agreements (collateralized by at least 102% U.S. Treasury and Agency Securities) 165,157 165,157 — — Total $ 184,969 $ 184,969 $ — $ —

Note 4 - Accounts Receivable,_2

Note 4 - Accounts Receivable, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	(in thousands) June 30, 2019 December 31, 2018 Accounts receivable $ 13,888 $ 9,246 Less allowance for uncollectible accounts receivable (110 ) (88 ) Accounts receivable, net $ 13,778 $ 9,158

Note 5 - Inventory, Net (Tables

Note 5 - Inventory, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) June 30, 2019 December 31, 2018 Raw materials $ 7,847 $ 6,169 Work in progress 47 190 Finished goods 2,063 1,408 Inventory, net $ 9,957 $ 7,767

Note 6 - Goodwill and Acquire_2

Note 6 - Goodwill and Acquired Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	As of June 30, 2019 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Licenses 5-10 $ 652 $ 602 $ 50 Total $ 652 $ 602 $ 50 As of December 31, 2018 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Licenses 5-10 $ 652 $ 591 $ 61 Total $ 652 $ 591 $ 61

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) June 30, 2019 December 31, 2018 Employee related expenses $ 4,339 $ 5,536 Corporate tax 1,616 1,616 Professional services 893 863 Royalties 836 1,354 Other accrued liabilities 1,543 1,522 Total accrued liabilities $ 9,227 $ 10,891

Note 10 - Share Option and Eq_2

Note 10 - Share Option and Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Cost of revenue $ 31 $ 59 $ 35 $ 125 Research and development 130 162 112 380 Sales and marketing 354 70 578 637 General and administrative 331 552 966 1,461 Total continuing operations 846 843 1,691 2,603 Discontinued operations - 79 - 143 Total share-based compensation $ 846 $ 922 $ 1,691 $ 2,746

Note 11 - Net Loss Per Share (T

Note 11 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended June 30, Six months ended June 30, ($ amounts in thousands) 2019 2018 2019 2018 Numerator Income (loss) from continuing operations $ 590 $ (5,733 ) $ (906 ) $ (13,919 ) Loss from discontinued operations - (738 ) - (2,878 ) Net income (loss) $ 590 $ (6,471 ) $ (906 ) $ (16,797 ) Denominator Weighted-average ordinary shares - basic 26,625,572 25,845,124 26,571,025 25,782,366 Dilutive effect of ordinary share equivalents resulting from ordinary share options and RSUs 263,660 - - - Weighted-average ordinary shares - diluted 26,889,232 25,845,124 26,571,025 25,782,366
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Options to purchase ordinary shares - 536,998 256,533 499,550 Unvested RSUs - 343,774 59,904 343,774

Note 12 - Commitments (Tables)

Note 12 - Commitments (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	($ amounts in thousands) Three months ended June 30, 2019 Six months ended June 30, 2019 Lease Cost Operating lease cost $ 319 $ 641 Short-term lease cost 39 229 Variable lease cost 116 271 Total lease cost $ 474 $ 1,141 Other Information Cash paid for amounts included in the measurement of lease liabilities $ 252 $ 515 Operating lease liabilities arising from obtaining right-of-use assets - - Operating Leases Weighted average remaining lease term (in years) 12.7 12.7 Operating Leases Weighted average discount rate 7.8 % 7.8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(in thousands) June 30, 2019 2019 $ 494 2020 1,029 2021 978 2022 972 2023 972 Thereafter 8,453 Total lease payments 12,898 Less: imputed interest (4,929 ) Total operating lease liabilities $ 7,969
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(in thousands) December 31, 2018 2019 $ 2,024 2020 1,848 2021 972 2022 855 2023 855 Thereafter 7,558 Total minimum lease payments $ 14,112
Purchase Obligation, Fiscal Year Maturity [Table Text Block]	(in thousands) Purchase obligations 2019 (six months) $ 7,795 2020 1,200 2021 1,200 2022 370 2023 370 Thereafter - Total minimum payments $ 10,935

Note 13 - Discontinued Operat_2

Note 13 - Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	(in thousands) Three months ended June 30, 2018 Six months ended June 30, 2018 Major classes of line items constituting loss from discontinued operations before income taxes: Service revenue $ 15,944 $ 27,819 Cost of service revenue 11,451 20,470 Gross profit 4,493 7,349 Research and development 1,534 2,912 Sales and marketing 2,235 4,489 General and administrative 1,462 2,826 Loss from discontinued operations before income taxes (738 ) (2,878 ) Income tax expense — — Loss from discontinued operations $ (738 ) $ (2,878 )

Note 1 - Business and Basis o_3

Note 1 - Business and Basis of Presentation (Details Textual) $ in Thousands	Nov. 06, 2018USD ($)	Jun. 30, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Entity Number of Employees	210
Accounts Receivable, after Allowance for Credit Loss, Current, Total		$ 13,778		$ 9,158
Operating Lease, Right-of-Use Asset		6,892
Operating Lease, Liability, Total		$ 7,969
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 7,200
Operating Lease, Liability, Total			$ 8,200
Quest [Member]
Proceeds from Divestiture of Businesses	$ 170,000

Note 1 - Business and Basis o_4

Note 1 - Business and Basis of Presentation - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Cash and cash equivalents	$ 187,291	$ 192,844
Restricted cash, non-current	100	100
Total cash, cash equivalents, and restricted cash	$ 187,391	$ 192,944	$ 66,463	$ 90,532

Note 2 - Revenue (Details Textu

Note 2 - Revenue (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 19,588,000	$ 16,657,000	$ 34,377,000	$ 28,336,000
UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax	$ 7,768,000	5,041,000	$ 13,299,000	8,739,000
Blood Donor Screening Services [Member]
Revenue from Contract with Customer, Including Assessed Tax		855,000		1,600,000
Blood Donor Screening Services [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		$ 855,000		$ 1,600,000

Note 2 - Revenue - Disaggregati

Note 2 - Revenue - Disaggregation of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue	$ 19,588	$ 16,657	$ 34,377	$ 28,336
UNITED STATES
Revenue	7,768	5,041	13,299	8,739
Europe and ROW [Member]
Revenue	2,199	2,237	4,961	4,473
Asia [Member]
Revenue	9,621	9,379	16,117	15,124
Product [Member]
Revenue	18,666	15,012	32,507	25,141
Service [Member]
Revenue	$ 922	$ 1,645	$ 1,870	$ 3,195

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement (Details Textual) - MidCap Agreement [Member] - MidCap Financial [Member] - USD ($) $ in Millions	Nov. 06, 2018	Sep. 25, 2018
Extinguishment of Debt, Amount	$ 32.3	$ 32.3
Debt Instrument, Prepayment and Exit Fees	$ 2.3	$ 2.3

Note 3 - Fair value Measureme_4

Note 3 - Fair value Measurement - Assets Measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Assets, Fair Value	$ 176,475	$ 184,969
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value	176,475	184,969
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value
Money Market Funds [Member]
Assets, Fair Value	10,833	19,812
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value	10,833	19,812
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value
Tri-party Repurchase Agreements [Member]
Assets, Fair Value	165,642	165,157
Tri-party Repurchase Agreements [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value	165,642	165,157
Tri-party Repurchase Agreements [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value
Tri-party Repurchase Agreements [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value

Note 3 - Fair value Measureme_5

Note 3 - Fair value Measurement - Assets Measured on Recurring Basis (Details) (Parentheticals)	Jun. 30, 2019	Dec. 31, 2018
US Treasury Securities [Member] | Minimum [Member]
Collateralized Percentage	102.00%	102.00%

Note 4 - Accounts Receivable,_3

Note 4 - Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable	$ 13,888	$ 9,246
Less allowance for uncollectible accounts receivable	(110)	(88)
Accounts receivable, net	$ 13,778	$ 9,158

Note 5 - Inventory, Net - Summa

Note 5 - Inventory, Net - Summary of Inventory, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Raw materials	$ 7,847	$ 6,169
Work in progress	47	190
Finished goods	2,063	1,408
Inventory, net	$ 9,957	$ 7,767

Note 6 - Goodwill and Acquire_3

Note 6 - Goodwill and Acquired Intangible Assets (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)
Number of Reporting Units	1
Disposal Group, Including Discontinued Operation, Goodwill				$ 1,500
Goodwill, Ending Balance		$ 2,483	$ 2,483

Note 6 - Goodwill and Acquire_4

Note 6 - Goodwill and Acquired Intangible Assets - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Net Carrying Amount, Finite-Lived Intangible Assets	$ 50	$ 61
Other Intangible Assets [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets	652	652
Accumulated Amortization, Finite-Lived Intangible Assets	602	591
Net Carrying Amount, Finite-Lived Intangible Assets	$ 50	$ 61
Other Intangible Assets [Member] | Minimum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	5 years	5 years
Other Intangible Assets [Member] | Maximum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	10 years	10 years
Technology-Based Intangible Assets [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 652	$ 652
Accumulated Amortization, Finite-Lived Intangible Assets	602	591
Net Carrying Amount, Finite-Lived Intangible Assets	$ 50	$ 61

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Employee related expenses	$ 4,339	$ 5,536
Corporate tax	1,616	1,616
Professional services	893	863
Royalties	836	1,354
Other accrued liabilities	1,543	1,522
Total accrued liabilities	$ 9,227	$ 10,891

Note 8 - Loans Payable (Details

Note 8 - Loans Payable (Details Textual) - MidCap Agreement [Member] - MidCap Financial [Member] - USD ($) $ in Millions	Nov. 06, 2018	Sep. 25, 2018	Oct. 04, 2016	Jun. 30, 2018
Debt Agreement, Maximum Borrowing Capacity			$ 40
Debt Agreement, Maximum Borrowing Capacity, Including Additional Increase			60
Payments for Loans	$ 32.3
Debt Instrument, Prepayment and Exit Fees	2.3	$ 2.3
Gain (Loss) on Extinguishment of Debt, Total	$ (2.1)
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 10
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.50%
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member]
Debt Instrument, Basis Spread on Variable Rate			4.45%
Term Loan [Member]
Long-term Debt, Total			$ 30	$ 30
Debt Instrument, Term			5 years
Debt Instrument, Periodic Payment, Term			2 years
Debt Instrument, Periodic Payment, Term, Potential Extension			4 years
Debt Agreement, Additional Increase			$ 10
Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate			7.60%

Note 9 - Share Capital (Details

Note 9 - Share Capital (Details Textual) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	323,181	694,322
Stock Issued During Period, Shares, Restricted Stock Award, Gross	44,586	83,378

Note 10 - Share Option and Eq_3

Note 10 - Share Option and Equity Incentive Plan (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 627,000	$ 713,000	$ 1,300,000	$ 1,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	5,600,000		$ 5,600,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years 255 days
Restricted Stock and Restricted Stock Units (RSU's) [Member]
Share-based Payment Arrangement, Expense	219,000	$ 209,000	$ 415,000	$ 1,000,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 3,700,000		$ 3,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			3 years
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	425,328		430,328
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 7.36		$ 7.35
2013 Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	142,544		142,544
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Second Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			40.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Third Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			30.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Fourth Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			30.00%
2013 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 14.44		$ 14.44
2013 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 16.42		$ 16.42

Note 10 - Share Option and Eq_4

Note 10 - Share Option and Equity Incentive Plan - Expense Recognized During the Year Related to Share-based Compensation Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Continuing Operations [Member]
Share-based compensation	$ 846	$ 843	$ 1,691	$ 2,603
Discontinued Operations [Member]
Share-based compensation		79		143
Continued and Discontinued Operations [Member]
Share-based compensation	846	922	1,691	2,746
Cost of Revenue [Member]
Share-based compensation	31	59	35	125
Research and Development Expense [Member]
Share-based compensation	130	162	112	380
Selling and Marketing Expense [Member]
Share-based compensation	354	70	578	637
General and Administrative Expense [Member]
Share-based compensation	$ 331	$ 552	$ 966	$ 1,461

Note 11 - Net Loss Per Share -

Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Net loss from continuing operations	$ 590		$ (5,733)		$ (906)	$ (13,919)
Less: Net loss from discontinued operations, net of tax			(738)			(2,878)
Net income (loss)	$ 590	$ (1,496)	$ (6,471)	$ (10,326)	$ (906)	$ (16,797)
Weighted-average ordinary shares - basic (in shares)	26,625,572		25,845,124		26,571,025	25,782,366
Dilutive effect of ordinary share equivalents resulting from ordinary share options and RSUs (in shares)	263,660
Weighted-average ordinary shares - diluted (in shares)	26,889,232		25,845,124		26,571,025	25,782,366

Note 11 - Net Loss Per Share _2

Note 11 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)		536,998	256,533	499,550
Restricted Stock and Restricted Stock Units (RSU's) [Member]
Antidilutive securities (in shares)		343,774	59,904	343,774

Note 12 - Commitments (Details

Note 12 - Commitments (Details Textual)	Sep. 25, 2018USD ($)ft²	Jun. 30, 2018USD ($)	Aug. 31, 2015USD ($)ft²	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)	Jul. 31, 2015ft²	Mar. 01, 2013
Lessee, Operating Lease, Term of Contract							5 years
Lessee, Operating Lease, Renewal Term			2 years
Area of Real Estate Property | ft²	9,000		22,100			7,600
Operating Leases, Monthly Rent Expense	$ 17,000
Lessee Leasing Arrangements, Operating Leases, Optional Extension of Contract			5 years
Operating Lease, Right-of-Use Asset				$ 6,892,000
Operating Lease, Liability, Total				$ 7,969,000
Office Expansion [Member]
Operating Leases, Monthly Rent Expense			$ 12,000
Minimum [Member]
Operating Leases, Monthly Rent Expense		$ 39,000	36,000
Maximum [Member]
Operating Leases, Monthly Rent Expense		$ 79,000	$ 39,000

Note 12 - Commitments - Lease E

Note 12 - Commitments - Lease Expense (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Lease Cost
Operating lease cost	$ 319	$ 641
Short-term lease cost	39	229
Variable lease cost	116	271
Total lease cost	474	1,141
Cash paid for amounts included in the measurement of lease liabilities	252	515
Operating lease liabilities arising from obtaining right-of-use assets
Weighted average remaining lease term (Year)	12 years 255 days	12 years 255 days
Weighted average discount rate	7.80%	7.80%

Note 12 - Commitments - Future

Note 12 - Commitments - Future Lease Payments (Details) $ in Thousands	Jun. 30, 2019USD ($)
2019	$ 494
2020	1,029
2021	978
2022	972
2023	972
Thereafter	8,453
Total lease payments	12,898
Less: imputed interest	(4,929)
Total operating lease liabilities	$ 7,969

Note 12 - Commitments - Futur_2

Note 12 - Commitments - Future Minimum Lease Payments under the Non-cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 2,024
2020	1,848
2021	972
2022	855
2023	855
Thereafter	7,558
Total minimum lease payments	$ 14,112

Note 12 - Commitments - Purchas

Note 12 - Commitments - Purchase Commitments (Details) $ in Thousands	Jun. 30, 2019USD ($)
2019 (six months)	$ 7,795
2020	1,200
2021	1,200
2022	370
2023	370
Thereafter
Total minimum payments	$ 10,935

Note 13 - Discontinued Operat_3

Note 13 - Discontinued Operations (Details Textual) - USD ($) $ in Millions	Nov. 06, 2018	Sep. 25, 2018	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2018
MidCap Agreement [Member] | MidCap Financial [Member]
Extinguishment of Debt, Amount	$ 32.3	$ 32.3
Debt Instrument, Prepayment and Exit Fees	$ 2.3	2.3
Laboratory Services Business [Member]
Proceeds from Divestiture of Businesses		170
Disposal Group, Including Discontinued Operation, Consideration		$ 27.9
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total			$ 146
Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue				$ 3.3	$ 5.5

Note 13 - Discontinued Operat_4

Note 13 - Discontinued Operations - Results of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Major classes of line items constituting loss from discontinued operations before income taxes:
Service revenue		$ 15,944		$ 27,819
Cost of service revenue		11,451		20,470
Gross profit		4,493		7,349
Research and development		1,534		2,912
Sales and marketing		2,235		4,489
General and administrative		1,462		2,826
Loss from discontinued operations before income taxes		(738)		(2,878)
Income tax expense
Loss from discontinued operations		$ (738)		$ (2,878)